论文部分内容阅读
目的评价阿托伐他汀钙联合尼莫地平防治蛛网膜下腔出血(SAH)迟发性脑血管痉挛(DCVS)的疗效。方法选择SAH患者68例,随机分为两组,每组34例,对照组给予尼莫地平治疗,实验组在对照组基础上加用阿托伐他汀钙进行治疗,观察两组的临床疗效。结果实验组在加用阿托伐他汀钙后再出血死亡1例,脑血管痉挛2例,脑血管痉挛发生率为6.1%;对照组再出血死亡2例,脑血管痉挛9例,脑血管痉挛发生率为28.1%,两组比较差异有统计学意义(P<0.05),实验组脑血管痉挛发生率低于对照组。结论阿托伐他汀钙联合尼莫地平能够防治SAH DCVS,可在临床上使用。
Objective To evaluate the efficacy of atorvastatin combined with nimodipine in the prevention and treatment of subarachnoid hemorrhage (SAH) -dependent cerebral vasospasm (DCVS). Methods Sixty-eight patients with SAH were randomly divided into two groups (34 in each group). The control group was treated with nimodipine. The experimental group was treated with atorvastatin calcium on the basis of the control group, and the clinical efficacy was observed. Results The experimental group was treated with atorvastatin calcium and then hemorrhage died in 1 case, cerebral vasospasm in 2 cases, cerebral vasospasm occurred in 6.1%; control group rebleeding died in 2 cases, cerebral vasospasm in 9 cases, cerebral vasospasm The incidence was 28.1%, the difference between the two groups was statistically significant (P <0.05), the incidence of cerebral vasospasm in the experimental group was lower than that of the control group. Conclusions Atorvastatin calcium combined with nimodipine can prevent and treat SAH DCVS and can be used clinically.